QUEBEC, Feb. 11 /CNW Telbec/ - Victhom Human Bionics Inc., "Victhom"
(TSX: VHB), announced today the filing of a patent application for the
detection and treatment of a physiological disorder that most likely leads to
sudden unexplainable death in epileptic patients during seizure.
Victhom has recently filed a patent application relating to a method and
device aimed at preventing sudden unexpected death in epilepsy (SUDEP) using
its neuromodulation platform.
Epilepsy is the most common neurological disorder, affecting about 1% of
the population worldwide. Current treatments that aim at treating seizures,
include neuromodulation devices for stimulation of the vagus nerve by
Cyberonics and a deep brain stimulation product, Medtronic's Intercept(TM)
Epilepsy Control System, which is currently in clinical trials. "The death
rate among epileptics is about three times that of age-matched cohorts. This
statistic may be explained by consequences of epilepsy, but in a surprising
number of cases, there is no obvious cause of death", said Mr. Nader Kameli,
Chief Operating Officer of Victhom's Neurobionix division. Sudden death from
unknown causes occurs in epileptics at a rate 24 times that of the general
population. In patients with severe, refractory epilepsy, SUDEP may account
for 50% of all deaths. While there is no toxicological or anatomical
explanation for SUDEP, evidence suggests a respiratory failure during seizure.
Research has revealed that SUDEP could be avoided by preventing and/or
treating both apnea and seizure, ensuring normal recovery from either or both
events. The monitoring by our technology of multiple physiological indicators
predisposing to SUDEP, like apnea and seizure activity, could be used, in
combination with the treatment of seizures, to detect the need for and then
apply a treatment for SUDEP. "We believe that our ability to detect and treat
apnea in a timely fashion by using our neuromodulation platform could prove to
be lifesaving for these patients. With this add-on therapy, we believe
existing devices would not only be able to treat seizures but also prevent
SUDEP that would result from respiratory dysfunction of failure", said Mr.
Kameli. He further said: "The body of knowledge in post mortem analysis of
these deaths suggests that abnormal respiratory patterns during seizure may
have led to an unrecoverable condition possibly causing death".
As Victhom develops its scientific knowledge in the field of respiration
and respiratory disorders, it continues to discover new and novel approaches
to treat various conditions using its neuromodulation technology for detection
and treatment. The current patent application is another sign of continued
progress in this field.
With the recent CE Mark approval of the Neurostep(TM) System, Victhom is
focused on the plans to introduce that product to the European market late
2009. Further developments in apnea and respiratory therapy will continue at
the research level. Victhom plans in partnering with leaders in the field of
epilepsy treatment to complete the development and introduction of this
therapy to the market.
About Victhom Human Bionics
Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix division focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix division develops biomechatronic
products to support or replace peripheral limbs in what is known as the
orthotics and prosthetics market.
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause Victhom's actual results, performance or achievements
to be materially different from those expressed or implied by any of Victhom's
statements. Actual events or results may differ materially. We disclaim any
intention, and assume no obligation, to update these forward-looking
For further information:
For further information: Nader Kameli, Chief Operating Officer,
Neurobionix division, Victhom Human Bionics Inc., (418) 872-5665, Fax: (418)
872-6926, email@example.com, www.victhom.com; Source: Victhom Human